share_log
Reuters ·  May 9 07:35
Intellia Therapeutics Inc - on Track to Initiate Phase 3 Study of Ntla-2002 for Treatment of Hereditary Angioedema (Hae) in 2H 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment